Avalo completes Phase 2 LOTUS enrollment for AVTX-009; topline data mid-2026

Avalo Therapeutics, Inc.

Enrolled ~250 patients, exceeding the 222-patient target.
Trial is randomized, double-blind, placebo-controlled with two AVTX-009 dose regimens.
Primary endpoint is HiSCR75 at Week 16; topline results expected mid-2026.
CEO Dr. Garry Neil cited strong investigator and patient engagement due to high unmet need.
Trial identifier NCT06603077; details at clinicaltrials.gov or lotustrial.com.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.